Current Health News Briefs Roundup

This content includes significant health-related news, such as Summit Therapeutics' cancer drug outperforming Keytruda, China's allowance of foreign-owned hospitals, and MBX Biosciences' valuation goals. Other highlights include mental health regulations, a case of mpox in India, and acquisition news in the healthcare sector.

Summit Therapeutics shares saw a dramatic 37% rise on Monday after a Chinese study demonstrated its experimental lung cancer drug's superior efficacy over Merck's Keytruda. The promising trial revealed remarkable patient survival rates, with a median survival time exceeding 11 months without disease progression.

China announced plans to allow the establishment of wholly foreign-owned hospitals in nine regions, including its capital. This policy aims to attract foreign investment and invigorate its sluggish economy. The initiative was part of a broader strategy discussed at the Central Committee led by Xi Jinping.

MBX Biosciences unveiled a goal to achieve a $482.5 million valuation in its U.S. IPO to fund its peptide therapies targeting endocrine and metabolic disorders. Meanwhile, Relay Therapeutics reported positive interim results from a breast cancer treatment, marking a meaningful advancement in patient care.

Other key developments include India's report of an mpox case in a traveler, the Biden administration's finalized rules for mental health service parity, and the FDA lifting a clinical hold on Rezolute Inc's low blood sugar treatment. Additionally, Swedish firm EQT's acquisition of GeBBS Healthcare Solutions and Terns Pharmaceuticals' promising obesity drug trial results made headlines.